FDA Approves New Oral Tx for Rare Heart Condition – Camzyos
Over the years few new specialty therapies have been approved for Cardiology conditions. That may be about to finally change with a recent FDA approval.
May 3, 2022
Over the years few new specialty therapies have been approved for Cardiology conditions. That may be about to finally change with a recent FDA approval.
We’ve written frequently on two of the biggest trends in channel access, the shift away from buy-and-bill to other, less costly, sites of service as
Limited distribution (LD) has contributed to the growth of a couple dozen specialty pharmacies over the past decade. When a pharmaceutical manufacturer selects a specialty pharmacy
Option Care Health announced that it has acquired the Specialty Pharmacy Nursing Network (SPNN) for $60 million in an all-cash transaction. SPNN will maintain its
The FDA approved the 35th biosimilar last week, Alymsys (bevacizumab-maly) from Amneal Pharmaceuticals, for seven cancer indications of the reference product, Avastin from Genentech. It
The National Home Infusion Association (NHIA) recently published the results of a survey of patients who had received a home chemotherapy infusion to gauge their
Last week the FDA approved a new ORAL specialty therapy, Vijoice (alpelisib) from Novartis Pharmaceuticals, indicated for breast cancer patients with evidence of mutation in
The FDA recently approved Opdualag (nivolumab and relatlimab-rmbw) from Bristol Myers Squibb, a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and
HIPAA…. the lurking threat to every specialty pharmacy. That’s a provocative statement….. but one that rings all too true. Each year we hear of yet
The FDA recently approved a new oral suspension therapy, Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients
